- Home
- FURY vs MURA Comparison
FURY vs MURA Comparison
Compare FURY & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- MURA
- Stock Information
- Founded
- FURY 2008
- MURA 2013
- Country
- FURY Canada
- MURA Ireland
- Employees
- FURY N/A
- MURA N/A
- Industry
- FURY Precious Metals
- MURA
- Sector
- FURY Basic Materials
- MURA
- Exchange
- FURY Nasdaq
- MURA Nasdaq
- Market Cap
- FURY 59.1M
- MURA 57.2M
- IPO Year
- FURY N/A
- MURA N/A
- Fundamental
- Price
- FURY $0.37
- MURA $3.34
- Analyst Decision
- FURY Strong Buy
- MURA Strong Buy
- Analyst Count
- FURY 1
- MURA 4
- Target Price
- FURY $2.00
- MURA $16.00
- AVG Volume (30 Days)
- FURY 86.1K
- MURA 262.8K
- Earning Date
- FURY 11-12-2024
- MURA 11-13-2024
- Dividend Yield
- FURY N/A
- MURA N/A
- EPS Growth
- FURY N/A
- MURA N/A
- EPS
- FURY N/A
- MURA N/A
- Revenue
- FURY N/A
- MURA N/A
- Revenue This Year
- FURY N/A
- MURA N/A
- Revenue Next Year
- FURY N/A
- MURA N/A
- P/E Ratio
- FURY N/A
- MURA N/A
- Revenue Growth
- FURY N/A
- MURA N/A
- 52 Week Low
- FURY $0.32
- MURA $2.88
- 52 Week High
- FURY $0.59
- MURA $6.25
- Technical
- Relative Strength Index (RSI)
- FURY 39.22
- MURA 36.64
- Support Level
- FURY $0.39
- MURA $3.32
- Resistance Level
- FURY $0.44
- MURA $4.20
- Average True Range (ATR)
- FURY 0.02
- MURA 0.23
- MACD
- FURY -0.00
- MURA -0.08
- Stochastic Oscillator
- FURY 0.00
- MURA 3.41
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.